National Healthcare Corp (NHC) valuation
National Healthcare P/E ratio history
National Healthcare trades at 23.2 times its earnings over the last twelve months. At its last 10 fiscal year ends its P/E ranged from 7.6 (year to Dec 2021) to 41.0 (year to Dec 2022), with a median of 19.9.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $137.09 | $7.67 | 17.9 |
| Dec 31, 2024 | $107.56 | $6.53 | 16.5 |
| Dec 31, 2023 | $92.42 | $4.34 | 21.3 |
| Dec 31, 2022 | $59.50 | $1.45 | 41.0 |
| Dec 31, 2021 | $67.94 | $8.99 | 7.6 |
| Dec 31, 2020 | $66.41 | $2.72 | 24.4 |
| Dec 31, 2019 | $86.43 | $4.44 | 19.5 |
| Dec 31, 2018 | $78.45 | $3.87 | 20.3 |
| Dec 31, 2017 | $60.94 | $3.70 | 16.5 |
| Dec 31, 2016 | $75.79 | $3.33 | 22.8 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
National Healthcare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| National HealthcareNHC | $3.22B | 23.2 | — | 2.1 |
| Tarsus PharmaceuticalsTARS | $3.22B | — | — | 5.3 |
| Amylyx PharmaceuticalsAMLX | $3.21B | — | — | — |
| Tango TherapeuticsTNGX | $3.29B | — | — | 61.1 |
| AtricureATRC | $3.10B | 291.7 | 170.7 | 5.5 |
| Disc MedicineIRON | $3.09B | — | — | — |
| CelcuityCELC | $3.37B | — | — | — |
| Surgery PartnersSGRY | $3.04B | — | 82.2 | 0.9 |
| Denali TherapeuticsDNLI | $3.01B | — | — | 834.1 |
| Peer median | 291.7 | 126.4 | 5.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NHC financials · NHC returns
No forecast, no recommendation. This page describes National Healthcare Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.